Skip to main content

Table 1 Baseline patient and disease characteristics of patients receiving treatment

From: Exploring treatment outcomes in Stage II-III rectal cancer patients undergoing neoadjuvant therapy at a tertiary care center in Pakistan: a comprehensive analysis of pathological outcomes

Patient and disease characteristics

Standard therapy (NT), n = 60, (%)

TNT, n = 17, (%)

Age in year

< 65

14 (23.3)

16 (94.1)

≥ 65

46 (76.6)

01 (5.9)

Gender

M

40(66.67)

08 (47.1)

F

20(33.33)

09 (52.94)

ECOG performance status scale

0

15(25)

01 (5.9)

1

41(68)

13 (76.5)

2

04(6.67)

03 (17.64)

Clinical stage

1

0 (00)

0 (00)

2

09 (15)

0 (00)

3

51 (85)

17 (100)

4

0(00)

0 (0.00)

Addiction

Smoker

18 (30.00)

05 (29.4)

Alcoholic

02(3.33)

01(5.8)

Unknown

40(66.66)

11 (64.7)

Comorbidities

Hypertension

15 (25.00)

03 (17.66)

Diabetes Mellitus

05 (8.33)

02 (11.76)

Ischemic Heart Disease

01 (1.66)

01 (5.88)

Hypo/Hyperthyroidism

0

01 (5.88)

Others (Tuberculosis, Asthma, Polio, Ulcerative Colitis)

0

0

Unknown

39 (65)

10 (58.82)

  1. ECOG Eastern cooperative oncology group performance status, TNT Total neoadjuvant treatment, NT Neoadjuvant